Chantest, Inc.

Cleveland, OH 44128

SBIR Award Summary

Total Number of Awards 8
Total Value of Awards $2.16MM
First Award Date 09/01/98
Most Recent Award Date 08/01/13

Key Personnel

Last Name Name Awards Contact
Lacerda Antonio E. Lacerda 4
Kramer James William Kramer 1
Bruening-Wright Andrew Hix Bruening-Wright 3
Brown Arthur M Brown 2

8 Awards Won

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-11-096
Budget: 08/01/13 - 07/31/14

DESCRIPTION (provided by applicant): Stem Cell-derived Human Cardiomyocytes (SC-hCMs) offer great potential for improving the accuracy of pre- clinical cardiac safety testing. We have characterized a population of SC-hCMs and have demonstrated that these cells show sensitive pharmacology that accurately predicts clinical responses. However, due ...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-11-096
Budget: 08/03/12 - 07/31/13

DESCRIPTION (provided by applicant): Stem Cell-derived Human Cardiomyocytes (SC-hCMs) offer great potential for improving the accuracy of pre- clinical cardiac safety testing. We have characterized a population of SC-hCMs and have demonstrated that these cells show sensitive pharmacology that accurately predicts clinical responses. However, due ...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-09-080
Budget: 07/15/10 - 12/31/10

DESCRIPTION (provided by applicant): Stem Cell-derived Human Cardiomyocytes (SC-hCMs) offer great potential for improving the accuracy of pre-clinical cardiac safety screening. We have recently characterized a population of SC-hCMs that will be made commercially available in 2010 by our collaborator GE Healthcare, and have demonstrated that thes...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-06-06
Budget: 09/30/06 - 03/31/08

DESCRIPTION (provided by applicant): Project Summary/Abstract: ChanTest's goal is to commercialize a comprehensive non-clinical proarrhythmic profile that will screen compounds through a battery of models that span from the molecular (ion channels) to the multicellular (Purkinje fibers) to whole organ (Langendorff perfused heart) and finally the...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 06/01/04 - 05/31/05

DESCRIPTION (provided by applicant): Atrial fibrillation (AF) is the most common cause of arrhythmias in the elderly; it has an incidence of more than 5 percent in people > 69 years of age. At present, there is no satisfactory treatment of this disease. The ChanTest Phase I SBIR was directed towards the discovery of novel drugs for this disease ...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 06/15/03 - 05/31/04

DESCRIPTION (provided by applicant): Atrial fibrillation (AF) is the most common cause of arrhythmias in the elderly; it has an incidence of more than 5 percent in people > 69 years of age. At present, there is no satisfactory treatment of this disease. The ChanTest Phase I SBIR was directed towards the discovery of novel drugs for this disease ...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 08/07/01 - 04/30/02

Atrial fibrillation (AF) is the commonest cardiac arrhythmia and in its chronic form affects more than two million patients in the USA. AF is associated with cardiac and non-cardiac diseases. About 10% of cases have no obvious cause (lone AF). Stroke is the commonest complication with a 25% greater risk than control in older age groups. Drugs th...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/01/98 - 08/31/99

DESCRIPTION (Adapted from the application): Chan Test Inc. is a drug testing company that provides customized contract services for lead screening of ion channels. Based on their experience over the past three years Chan Test has developed successful protocols that meet the unique needs of each of their ...